About Valgen

Hangzhou Valgen Medtech Co., Ltd. ( Valgen Medtech) is dedicated to the interventional treatment of structural heart diseases. Founded in 2015 in Hangzhou, Valgen Medtech applied for more than 500 patents worldwide by the end of 2023. More than 150 patents were granted. Three independently-developed products passed the "Special Review of Innovative Medical Devices". Multiple interventional therapy devices, including the Dragon series, will greatly enrich clinical options in structural heart disease treatment.

The DragonFly™ Transcatheter Mitral Valve Repair System, as the first transfemoral vein edge-to-edge repair product developed in-house in China, passed its review in accordance with the Special Review Procedure for Innovative Medical Devices in March 2021. The product was granted marketing approval in China by the NMPA on November 29, 2023. The development of the product was supported by the National Key R&D Program for the "14th Five-Year Plan". In addition to the DragonFly™, Valgen Medtechs marketed products include the Pu Jie Jie™ Medical Radiation Protective Shield, Magpie™ Balloon Dilatation Catheter, DragonPath™ Transseptal Puncture System, Firework™ Stiff Guidewires, etc.

Valgen Medtech is headquartered in Hangzhou High-Tech Zone (Binjiang) Hangzhou and established an R&D center in Shenzhen. It has been accredited as a national and provincial (Zhejiang) technology-oriented SME, a high and new technology R&D center, and engineering research center in Hangzhou. Valgen adheres to the corporate strategy of being located in China and facing the world, further accelerating the development and clinical application of innovative treatment technology that addresses unmet clinical needs and continuously provides better solutions for patients around the world.